Risk of Developing Cryoglobulins in Relation to Serum HCV-RNA, Length of Exposure to HCV, and Serum Anti-HIV in Hemophiliacs
| Risk Factor . | No. of Patients . | Odds Ratio (95% CI) . | Odds Ratio Adjusted for HIV (95% CI) . |
|---|---|---|---|
| Serum HCV-RNA | 114 | 4.9 (1.1-22.0) | 4.5 (1.0-20.7) |
| HCV exposure | |||
| 10-17 yr | 24 | 1 | 1 |
| 18-21 yr | 27 | 2.4 (0.6-10.8) | 2.3 (0.5-10.3) |
| 22-26 yr | 46 | 3.7 (1.0-14.4) | 3.4 (0.9-13.8) |
| >26 yr | 31 | 4.4 (1.1-18.0) | 4.0 (0.9-17.2) |
| Anti-HIV (+) | 135 | 1.6 (0.8-3.2) | — |
| Risk Factor . | No. of Patients . | Odds Ratio (95% CI) . | Odds Ratio Adjusted for HIV (95% CI) . |
|---|---|---|---|
| Serum HCV-RNA | 114 | 4.9 (1.1-22.0) | 4.5 (1.0-20.7) |
| HCV exposure | |||
| 10-17 yr | 24 | 1 | 1 |
| 18-21 yr | 27 | 2.4 (0.6-10.8) | 2.3 (0.5-10.3) |
| 22-26 yr | 46 | 3.7 (1.0-14.4) | 3.4 (0.9-13.8) |
| >26 yr | 31 | 4.4 (1.1-18.0) | 4.0 (0.9-17.2) |
| Anti-HIV (+) | 135 | 1.6 (0.8-3.2) | — |